Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

T2952

Sigma-Aldrich

Tetrabenazine

≥98% (HPLC), solid

Sinônimo(s):

9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-3-isobutyl-(rel 3R,11bR)-2H-benzo[a]quinolizin-2-one

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C19H27NO3
Número CAS:
58-46-8
Peso molecular:
317.42
Beilstein:
40090
Número CE:
200-383-6
Número MDL:
MFCD08461052
Código UNSPSC:
12352200
ID de substância PubChem:
329826731
NACRES:
NA.77

Ensaio

≥98% (HPLC)

Formulário

solid

solubilidade

DMSO: >10 mg/mL
H2O: insoluble

originador

Roche

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

COc1cc2CCN3C[C@@H](CC(C)C)C(=O)CC3c2cc1OC

InChI

1S/C19H27NO3/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21/h8-9,12,14,16H,5-7,10-11H2,1-4H3/t14-,16-/m1/s1

chave InChI

MKJIEFSOBYUXJB-GDBMZVCRSA-N

Procurando produtos similares? Visita Guia de comparação de produtos

Aplicação

Tetrabenazine has been used for dopamine uptake assays in mouse brain cells1. Tetrabenazine has also been used for non-specific binding assays in postnuclear supernatants derived from PC-12 and CV-1 cells2.

Ações bioquímicas/fisiológicas

Tetrabenazine is a reversible type 2 vesicular monoamine transporter (VMAT) inhibitor.
Tetrabenazine is a reversible type 2 vesicular monoamine transporter (VMAT) inhibitor. It depletes dopamine stores.

Características e benefícios

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Nota de preparo

Tetrabenazine is soluble in DMSO at a concentration that is greater than 10 mg/ml and is insoluble in water.

Pictogramas

Exclamation mark
GHS07

Palavra indicadora

Warning

Frases de perigo

H302

Declarações de precaução

P264 - P270 - P301 + P312 - P501

Classificações de perigo

Acute Tox. 4 Oral

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

dust mask type N95 (US), Eyeshields, Gloves

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
113M4766V
079K4719V
028K46273
059K46201
059K4620

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Joseph Jankovic et al.
Expert review of neurotherapeutics, 11(11), 1509-1523 (2011-10-22)
Tetrabenazine (TBZ; Xenazine) is a potent, selective, reversible depletor of monoamines from nerve terminals. TBZ inhibits the vesicular monoamine transporter type 2 which, in humans, is expressed nearly exclusively in the brain. TBZ is rapidly metabolized in the liver by
Hongyu Wang et al.
Molecular neurodegeneration, 5, 18-18 (2010-04-28)
Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) expansion in Huntingtin protein (Htt). PolyQ expansion in Httexp causes selective degeneration of striatal medium spiny neurons (MSN) in HD patients. A number of previous studies suggested that
Catarina A Owesson-White et al.
Journal of neurochemistry, 121(2), 252-262 (2012-02-03)
Mesolimbic dopamine neurons fire in both tonic and phasic modes resulting in detectable extracellular levels of dopamine in the nucleus accumbens (NAc). In the past, different techniques have targeted dopamine levels in the NAc to establish a basal concentration. In
Nicolaas I Bohnen et al.
Neurology, 81(18), 1611-1616 (2013-10-01)
We investigated dopaminergic and cholinergic correlates of gait speed in Parkinson disease (PD) and non-PD control subjects to test the hypothesis that gait dysfunction in PD may result from multisystem degeneration. This was a cross-sectional study. Subjects with PD but
Roger L Albin et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(6), 887-893 (2013-04-11)
We evaluated PET-based classification of neurodegenerative pathology in mild cognitive impairment (MCI). Our study was a cross-sectional and prospective evaluation of a cohort of 27 MCI subjects drawn from a university-based cognitive disorders clinic. We compared expert clinical consensus classification
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica